Argos Therapeutics, Inc. Stock

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 278K 256K 237K 449K 30.29M 457K 3.06M 1.2M 14.92M 1.19M 1.17M 51.3M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.01M 3.7M 3.42M 6.48M 437M 6.59M 44.2M 17.36M 215M 17.22M 16.84M 741M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news : Argos Therapeutics, Inc.

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
13/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
22/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
22/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
04/12/18	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
REGENERON PHARMACEUTICALS, INC.	-1.37%	+1.25%	+15.31%	-8.75%	67.61B
UCB	-0.46%	-7.35%	+36.60%	+199.95%	51.6B
SAMSUNG BIOLOGICS CO.,LTD.	+0.36%	+40.00%	+40.00%	+40.00%	43B
CSL LIMITED	-1.26%	-0.39%	-49.63%	-53.84%	40.94B
BIOGEN INC.	+1.40%	-2.81%	+52.21%	-27.11%	29.4B
MODERNA, INC.	+0.98%	-15.33%	+110.71%	-45.30%	27.09B
INCYTE CORPORATION	-2.16%	-0.95%	+63.65%	+84.90%	23.32B
INNOVENT BIOLOGICS, INC.	-0.67%	+1.48%	+10.61%	+188.35%	19.92B
SWEDISH ORPHAN BIOVITRUM AB	-2.14%	-3.88%	+56.19%	+130.70%	16.91B
Average	-0.51%	-3.58%	+37.30%	+56.54%	31.98B
Weighted average by Cap.	-0.55%	-3.06%	+30.62%	+47.40%

	2016	2017
Net sales	945K 827K 763K 705K 1.34M 90.17M 1.36M 9.11M 3.58M 44.42M 3.55M 3.47M 153M	1.9M 1.66M 1.53M 1.42M 2.69M 181M 2.73M 18.31M 7.19M 89.24M 7.13M 6.98M 307M
Net income	-53.03M -46.38M -42.78M -39.51M -74.98M -5.06B -76.24M -511M -201M -2.49B -199M -195M -8.57B	-40.58M -35.49M -32.74M -30.24M -57.37M -3.87B -58.34M -391M -154M -1.91B -152M -149M -6.55B
Net Debt	-13.11M -11.47M -10.58M -9.77M -18.53M -1.25B -18.85M -126M -49.62M -616M -49.22M -48.15M -2.12B	4.27M 3.73M 3.44M 3.18M 6.03M 407M 6.14M 41.14M 16.15M 200M 16.02M 15.67M 689M

Argos Therapeutics, Inc. Stock

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news : Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile